Regeneron and Eli Lilly are
now asking regulators to expand authorization on their antibody treatments just
one day after promising new research was released.
Right now both companies
produce treatments that have been approved for emergency use in mild or
moderate COVID-19 cases.
But as News 12 has reported,
this new research shows that these treatments can significantly reduce the risk
of infection, hospitalization, and death in high risk cases.
Regulators say they are
holding off on a decision until more research is done.